Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00

Posted by AM Reporter Staff on Aug 6th, 2022

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price target boosted by Oppenheimer from $125.00 to $150.00 in a research note released on Wednesday morning, The Fly reports.

Several other brokerages also recently weighed in on SRPT. The Goldman Sachs Group cut their price objective on shares of Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating on the stock in a research report on Tuesday, May 24th. StockNews.com downgraded shares of Sarepta Therapeutics from a buy rating to a hold rating in a research report on Saturday, May 21st. Needham & Company LLC lifted their price objective on shares of Sarepta Therapeutics from $150.00 to $162.00 and gave the company a buy rating in a research report on Friday, July 29th. Morgan Stanley cut their price objective on shares of Sarepta Therapeutics from $77.00 to $74.00 and set an equal weight rating on the stock in a research report on Thursday, May 19th. Finally, Cantor Fitzgerald cut their price objective on shares of Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating on the stock in a research report on Friday, June 24th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and a consensus price target of $126.92.

Sarepta Therapeutics Trading Up 4.5 %

Sarepta Therapeutics stock opened at $106.02 on Wednesday. The firm’s 50-day moving average is $78.23 and its 200-day moving average is $76.58. The company has a debt-to-equity ratio of 1.52, a quick ratio of 5.13 and a current ratio of 4.53. Sarepta Therapeutics has a 1 year low of $61.28 and a 1 year high of $107.03. The company has a market cap of $9.28 billion, a P/E ratio of -18.06 and a beta of 1.27.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.15. Sarepta Therapeutics had a negative net margin of 60.66% and a negative return on equity of 67.98%. The company had revenue of $210.83 million for the quarter, compared to the consensus estimate of $208.25 million. During the same period last year, the firm posted ($2.10) EPS. The company’s revenue for the quarter was up 43.5% on a year-over-year basis. On average, equities analysts expect that Sarepta Therapeutics will post -4.48 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in the business. Inspire Investing LLC purchased a new position in shares of Sarepta Therapeutics in the first quarter worth approximately $234,000. Xponance Inc. grew its position in Sarepta Therapeutics by 9.0% during the fourth quarter. Xponance Inc. now owns 9,332 shares of the biotechnology company’s stock valued at $840,000 after purchasing an additional 772 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $1,813,000. AlphaCrest Capital Management LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $799,000. Finally, Neo Ivy Capital Management purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $405,000. Institutional investors and hedge funds own 81.43% of the company’s stock.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.